Composition, Clinical Efficiency, and Mechanism of NHC-Approved “Three Chinese Medicines and Three Chinese Recipes” for COVID-19 Treatment

Ke-Yao Xia¹, Zeyuan Zhao², Taif Shah², Jing-Yi Wang¹ and Zulqarnain Baloch²*

¹Faculty of Traditional Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR, China, ²Faculty of Life Science and Technology, Yunnan Provincial Center for Molecular Medicine, Kunming University of Science and Technology, Kunming, China

Traditional Chinese medicines (TCMs) have been regularly prescribed to treat and prevent diseases for thousands of years in the eastern part of the Asian continent. Thus, when the coronavirus disease 2019 (COVID-19) epidemic started, TCM was officially incorporated as a strategy by the National Health Commission (NHC) for the treatment of COVID-19 infection. TCMs were used to treat COVID-19 and had a significant effect on alleviating symptoms, delaying disease progression, improving the cure rate, and reducing the mortality rate in China. Therefore, China’s National Health Commission officially approved Qingfei Paidu decoction, Xuanfei Baidu decoction, Huashi Baidu decoction, Lianhua Qingwen capsules, Jinhua Qinggan granules, and Xuebijing for COVID-19 treatment. This review evaluates and summarizes the use of TCMs against infectious diseases and the composition, clinical efficacy, and mechanisms of the NHC-approved “three Chinese medicines and three Chinese recipes” for COVID-19 treatment. The three Chinese medicines and three Chinese recipes have been demonstrated to be highly effective against COVID-19, but there is a lack of in vivo or in vitro evidence. Most of the available data related to the potential mechanism of the three Chinese medicines and three Chinese recipes is based on virtual simulation or prediction, which is acquired via molecular docking and network pharmacology analysis. These predictions have not yet been proven. Therefore, there is a need for high-quality in vivo and in vitro and clinical studies by employing new strategies and technologies such as genomics, metabolomics, and proteomics to verify the predicted mechanisms of these drug’s effects on COVID-19.

Keywords: coronaviruses, COVID-19, traditional Chinese medicine (TCM), san-yao san-fang, three Chinese medicine and three Chinese recipes

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in December 2019 in Wuhan, China. As this disease spread rapidly due to its strong contagiousness, long incubation periods, and high pathogenicity, the World Health Organization (WHO) first declared the epidemic as a public health emergency of international concern on January 30, 2020. Moreover, COVID-19 was declared a...
for COVID-19 treatment. Approved three Chinese medicines and three Chinese recipes composition, clinical efficacy, and mechanisms of NHC-approved three Chinese medicines and three Chinese recipes for COVID-19 treatment.

TCM APPLICATION AGAINST INFECTIOUS DISEASES

Based on the valuable experience of understanding life, maintaining health, production, and medical practice, TCM has been regularly prescribed to treat and prevent diseases for thousands of years in the eastern part of the Asian continent (Liu et al., 2020a). According to literature, TCM prescription against infectious diseases was first described in Huangdi Neijing in 200 BC (Cavalieri and Rotoli, 1997). The classical TCM book, Shanghan Lun (Treatise on Cold Damage Diseases as the first time that Yinqiao powder, Xuanbai Chengqi decoction, and Sanren decoction can be used for the treatment of infectious diseases (Huang, 2002). TCM, such as Lianhua Qingwen extracts, has been used to treat influenza viruses (Ding and Giannoumis, 2017). During the 2002–2003 severe acute respiratory syndrome (SARS) outbreaks in China, TCM was widely used in combination with Western medicine to treat SARS cases. According to the reports, the combination of TCM and Western medicine can effectively improve clinical symptoms and hypoxemia and protect the functions of the lung and heart (Jia and Gao, 2003). In short, TCM has been shown to possess antiviral activities against various viruses including herpes simplex virus, hepatitis B and C viruses, influenza virus, human immunodeficiency virus, SARS-CoV, MERS-CoV, etc. (Huang et al., 2021).

THREE CHINESE MEDICINES AND THREE CHINESE RECIPES

Based on the successful application of TCMs against SARS and H1N1 influenza, China NHC has suggested TCM administration as a treatment strategy against COVID-19 (Wang and Qi, 2020). However, TCM has been officially incorporated as a strategy by the NHC for the diagnosis and treatment of COVID-19. The Chinese COVID-19 treatment method was also accepted by the director-general of the WHO senior adviser, Bruce Elwald (Zhao et al., 2021a). When we searched with the keywords “Chinese medicine” and “COVID-19” on September 12, 2021, 4,174 articles had been published on PubMed, which shows that there has been a lot of research conducted based on TCMs and reveals that TCM has recovered COVID-19 patients’ symptoms and stopped the progression of the disease from mild to severe (Zhou et al., 2021a).

Three Chinese medicines and three Chinese recipes were indeed used from the onset of COVID-19 in different parts of China, but JHQG, LHQW, and XBJ were first proposed in the national guidelines for the diagnosis and treatment of novel coronavirus pneumonia (interim 8th version) published by the China National Health Commission (NHC), “three Chinese medicines and three Chinese recipes” (三药三方) have been officially approved for COVID-19 treatment, including Qingfei Paidu decoction (QFPD), Xuanfei Baidu decoction (XFBD), Huashi Baidu decoction (HSBD), Lianhua Qingwen capsules (LHQW), Jinhua Qinggan granules (JHQG), and Xuebijing injection (XBJ) (Commission, 2019). This review evaluates and summarizes the use of TCMs against infectious diseases and the composition, clinical efficacy, and mechanisms of NHC-approved three Chinese medicines and three Chinese recipes for COVID-19 treatment.

Coronaviruses (CoVs) are a large group of viruses (Fehr and Perlman, 2015), consisting of hundreds of viruses, that generally causes mild to moderate respiratory system infections, such as flu, common cold, etc. Traditional Chinese medicine (TCM) has successfully treated infectious and non-infectious diseases for thousands of years. During the COVID-19 outbreak in Wuhan, China’s national government appointed 3,100 TCM doctors at Wuhan and appointed TCM experts to screen and formulate effective TCM prescriptions for COVID-19 (Ren et al., 2020a). TCM had a significant effect on COVID-19, alleviating symptoms, delaying disease progression, improving cure rate, and reducing mortality rate (Ren et al., 2020b). Therefore, TCM has attained significant practical experience and a basis for long-term epidemic or pandemic prevention and treatment. According to the latest guidelines on the diagnosis and treatment of novel coronavirus pneumonia (interim 8th version) published by the China National Health Commission (NHC), “three Chinese medicines and three Chinese recipes” (三药三方) have been officially approved for COVID-19 treatment, including Qingfei Paidu decoction (QFPD), Xuanfei Baidu decoction (XFBD), Huashi Baidu decoction (HSBD), Lianhua Qingwen capsules (LHQW), Jinhua Qinggan granules (JHQG), and Xuebijing injection (XBJ) (Commission, 2019). This review evaluates and summarizes the use of TCMs against infectious diseases and the composition, clinical efficacy, and mechanisms of NHC-approved three Chinese medicines and three Chinese recipes for COVID-19 treatment.

Three Chinese medicines and three Chinese recipes were indeed used from the onset of COVID-19 in different parts of China, but JHQG, LHQW, and XBJ were first proposed in the national guidelines for the diagnosis and treatment of novel coronavirus pneumonia (interim 8th version) published by the China National Health Commission (NHC), “three Chinese medicines and three Chinese recipes” (三药三方) have been officially approved for COVID-19 treatment, including Qingfei Paidu decoction (QFPD), Xuanfei Baidu decoction (XFBD), Huashi Baidu decoction (HSBD), Lianhua Qingwen capsules (LHQW), Jinhua Qinggan granules (JHQG), and Xuebijing injection (XBJ) (Commission, 2019). This review evaluates and summarizes the use of TCMs against infectious diseases and the composition, clinical efficacy, and mechanisms of NHC-approved three Chinese medicines and three Chinese recipes for COVID-19 treatment.

TCM APPLICATION AGAINST INFECTIOUS DISEASES

Based on the valuable experience of understanding life, maintaining health, production, and medical practice, TCM has been regularly prescribed to treat and prevent diseases for thousands of years in the eastern part of the Asian continent (Liu et al., 2020a). According to literature, TCM prescription against infectious diseases was first described in Huangdi Neijing in 200 BC (Cavalieri and Rotoli, 1997). The classical TCM book, Shanghan Lun (Treatise on Cold Damage Diseases as the first time that Yinqiao powder, Xuanbai Chengqi decoction, and Sanren decoction can be used for the treatment of infectious diseases (Huang, 2002). TCM, such as Lianhua Qingwen extracts, has been used to treat influenza viruses (Ding and Giannoumis, 2017). During the 2002–2003 severe acute respiratory syndrome (SARS) outbreaks in China, TCM was widely used in combination with Western medicine to treat SARS cases. According to the reports, the combination of TCM and Western medicine can effectively improve clinical symptoms and hypoxemia and protect the functions of the lung and heart (Jia and Gao, 2003). In short, TCM has been shown to possess antiviral activities against various viruses including herpes simplex virus, hepatitis B and C viruses, influenza virus, human immunodeficiency virus, SARS-CoV, MERS-CoV, etc. (Huang et al., 2021).
coronavirus pneumonia of COVID-19 (interim 4th version) on January 27, 2020 (National Health Commission of the People’s Republic of China, 2020a). However, QFPD, XFBD, and HSBD were first mentioned in the national guidelines for the diagnosis and treatment of novel coronavirus pneumonia of COVID-19 (interim 6th version) on February 28, 2020 (National Health Commission of the People’s Republic of China, 2020b). Then, on March 18, 202, these six TCMs were named as the “three Chinese medicines and three Chinese recipes” (Medicineo NAoTC XXXX). These medicines’ applications were classified according to disease severity.

QFPD was developed by Ge YW, based on four prescriptions (MXSG, SGMH, XCH, and WLS) from the classic TCM book by Shang Han Lun, a distinguished researcher at the China Academy of Chinese Medical Sciences (Medicineo NAoTC XXXb). A total of 214 COVID-19 patients received QFPD in four provinces, with an effectiveness rate of more than 90% (Medicineo NAoTC XXXc). Thus, the National Administration of TCM recommended QFPD for COVID-19 treatment on February 7, 2020 (Medicineo NAoTC XXXd). Furthermore, guidelines on the diagnosis and treatment of novel coronavirus disease (interim 6th version) published by the NHC recommend QFPD for the treatment of COVID-19 (National Health Commission of the People’s Republic of China, 2020b). XFBD was designed based on MXSG, MXYG, QJWJ, and TLDZXF prescriptions from the classic TCM book named Shang Han Lun. A study was conducted in Traditional Chinese Medicine Wuhan Hospital in Hubei Province. The results showed that the Xuanfei-Baidu formula had a significant anti-inflammatory effect apart from improving the lymphocyte count of COVID-19 patients (Medicineo NAoTC XXXe). Therefore, XFBD was recommended by NHC in the guidelines on the diagnosis and treatment of novel coronavirus pneumonia to treat COVID-19 on February 28, 2020 (National Health Commission of the People’s Republic of China, 2020b). HSBD was developed by Chinese academician Huang and his team based on MXSG, HXZQ, XBCQ, and TLDZXF prescriptions written in Shang Han Lun, a classic TCM book written by Zhang Zhongjing, and Yinqiao powder in Wen Bing Tiao Bian by WU Jutong (Lin et al., 2020). Jinhua Qinggan granules is a Chinese medicine prescription developed by experts working in the Beijing Administration of Traditional Chinese Medicine. JHQG was recommended to use against an avian influenza A (H1N1) virus and was very effective against H1N1 (China MoHotPsRo, 2009). Additionally, JHQG could also improve the immune function of influenza patients (Qi and Wang, 2016). Therefore, NHC also recommended JHQG for the treatment of COVID-19 in the guidelines (interim 4th version) issued by the NHC on January 27, 2020 (National Health Commission of the People’s Republic of China, 2020a). XBJ injection is a patent TCM developed in 2003 and is mainly based on a classic TCM prescription called Xuefu Zhuyu decoction. XBJ was first used to treat influenza, MERS, dengue, and Ebola (Tong et al., 2020). XBJ has also been recommended to treat critical COVID-19 cases in the guidelines (interim 4th version) (National Health Commission of the People’s Republic of China, 2020a).

### The Composition of Three Chinese Medicines and Three Chinese Recipes

We compared the composition of the six most effective recipes of three Chinese medicines and three Chinese recipes for COVID-19 treatment (Table 1). There are 50 total TCM compounds; among them, 47 are Chinese herbs, two fungi, and one mineral; of these, 14 components are common in five NHC-approved drugs for COVID-19. Ephedrae Herba, Glycyrrhizae Radix et Rhizoma (甘草), Armeniacae Semen Amarum (苦杏仁), and Gypsum Fibrosum (石膏) are the common herbs among HSBD, LHQW, XFBD, LHQW, and JHQG. Lonicerae Japonicae Flos (金银花), Forsythiae Fructus (连翘), and Menthae Haplocaltcis Herba (薄荷) are common herbs of HSBD and JHQG. Atractylodis Rhizoma (苍术) and Descurainiae Semen Lepidii Semen (薏苡仁) are common in HSBD and XFBD. Scutellariae Radix (黄芩) is the common herb in QFPD and JHQG. Ageratum rugosum (藿香) is common in HSBD and QFPD. Atractylodis Rhizoma (苍术) is common in HSBD and XFBD. Pogostemonis Herba (广藿香) is common in XFBD and LHQW. Artemisiae Annuae Herba (青蒿) is common in XFBD and JHQG. Descurainiae Semen Lepidii Semen (薏苡仁) is common in HSBD and XFBD. Poria (茯苓) is common in HSBD and QFPD. The other 37 components are added individually in different drugs. We observed that the compositions of oral drugs are complex compared to injectables. Interestingly, the composition of injectables is different compared to other drugs (Table 1).

Of these herbs, Armeniacae Semen Amarum and Ephedrae Herba are two of the most commonly used herbs for the treatment of mild, moderate, and severe COVID-19 infection (Ang et al., 2020; Huang et al., 2021). In addition, Scutellariae Radix, Forsythiae Fructus, Ageratum rugosum, and Atractylodis
| Ingredients (Chinese)* | HSBD | OFPD | XFBD | LHOW | JHGQ | XBJ | References |
|-----------------------|------|------|------|------|------|-----|------------|
| Ephedrae Herba (麻黄) | √    | √    | √    | √    | √    | ×   | Tao et al. (2013), Ding et al. (2017), Liu et al. (2020c), Pan et al. (2020), Zhuang et al. (2020) |
| Glycyrrhizae Radix et Rhizoma (甘草) | √    | √    | √    | √    | √    | ×   | Tao et al. (2013), Ding et al. (2017), Liu et al. (2020c), Pan et al. (2020), Zhuang et al. (2020) |
| Amarniaca Semen Amarun (黄芩) | √    | √    | √    | √    | √    | ×   | Tao et al. (2013), Ding et al. (2017), Liu et al. (2020c), Pan et al. (2020), Zhuang et al. (2020) |
| Cinnamomae Ramulus (桂枝) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Alismatis Rhizoma (泽泻) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Atractylodis Macrocephalae Rhizoma (白术) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Bupleuri Radix (柴胡) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Scutellariae Radix (黄芩) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Pinelliae Rhiza Praeparatum Cum Zingiberis Rhiza Pecans (生姜) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Zingiberis Rhiza Pecans (生姜) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Asteris Radix et Rhizoma (紫菀) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Farfarae Flos (紫花) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Belamcandae Rhizoma (射干) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Asari Radix et Rhizoma (细辛) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Dioscoreae Rhizoma (山药) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Aurantii Fructus Immaturus (枳实) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Citri Reticulatae Pericarpium (陈皮) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Ageratum rugose (蔓荆) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Coicis Semen (夏枯草) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Atractyloidis Rhizoma (苍术) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Pogostemonis Herba (广藿香) | x    | x    | x    | x    | x    | x   | Tao et al. (2013), Ding et al. (2017), Commission (2020c), Pan et al. (2020), Zhuang et al. (2020) |
| Artemisiae Annuae Herba (蒿) | x    | x    | x    | x    | x    | x   | Liu et al. (2020c), National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020), Zhuang et al. (2020) |
| Polygoni Cuspidati Rhizoma et Radix (虎杖) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Verbenae Herba (马鞭草) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Phragmites Rhizoma (芦根) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Descurainiae Semen Lepidii Semen (葶苈子) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Citri Grandis Exocarpium (化橘红) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Mangnoliae Officinalis Cortex (厚朴) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Tsaoko Fructus (草果) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020) |
| Pinelliae Rhiza Praeparatum (法半夏) | x    | x    | x    | x    | x    | x   | National Health Commission of the People’s Republic of China (2020c), Pan et al. (2020), Zhuang et al. (2020) |
| Rhei Radix et Rhizoma (大黄) | x    | x    | x    | x    | x    | x   | Tao et al. (2013), Ding et al. (2017), Commission (2020c), Pan et al. (2020), Zhuang et al. (2020) |

(Continued on following page)
### TABLE 1 | (Continued) Composition of the National Health Commission (NHC)-approved Chinese drugs against COVID-19.

| Ingredients (Chinese)* | HSBD | QFPD | XFBD | LHQW | JHQG | XBJ | References |
|------------------------|------|------|------|------|------|-----|------------|
| Astragali Radix (黄芪) | √    |      |      |      |      |     |            |
| Paeoniae Radix Rubra (赤芍) | √    |      |      |      |      |     |            |
| Lonicerae Japonicae Flos (金银花) | ×     | ×     |      |      | √    |     |            |
| Forsythiae Fructus (连翘) | ×     | ×     | ×     | √    |      |     |            |
| Houttuyniae Herba (魚腥草) | ×     | ×     | ×     |      |      |     |            |
| Angelicae Sinensis Radix (当归) | ×     | ×     | ×     |      |      |     |            |
| Gypsum Fibrosum (石膏) | √     | √     | √     |      | √    |     |            |
| Poria (茯苓) | √     |      |      | x    | x    |     |            |
| Polyporus (猪苓) | x     |      |      | x    | x    |     |            |
| references |      |      |      |      |      |     |            |

### TABLE 2 | Application of TCM against different symptoms of COVID-19 recommended by China National Health Commission (NHC) (National Health Commission of the People’s Republic of China, 2020c).

| Symptoms            | HSBD | QFPD | XFBD | LHQW | JHQG | XBJ |
|---------------------|------|------|------|------|------|-----|
| Cough               | √    |      |      |      |      |     |
| Fever               | √    | √    |      |      |      |     |
| Short breath        | √    | √    |      |      |      |     |
| Fatigue             | √    |      |      |      |      |     |
| Muscle or body aches | x    |      |      |      |      |     |
| Headache            | x    |      |      |      |      |     |
| Sore throat         | x    |      |      |      |      |     |
| Nausea              | x    |      |      |      |      |     |
| Expectoration       | x    |      |      |      |      |     |
| Dyspnea             | x    |      |      |      |      |     |
| Shock               | x    |      |      |      |      |     |

Rhizoma are used to cure mild and moderate COVID-19 infection (Ang et al., 2020; Huang et al., 2021). Notably, Glycyrhizae Radix et Rhizoma is commonly used to cure mild, moderate, and severe COVID-19 patients (Ang et al., 2020; Huang et al., 2021). It has been reported that Lonicerae Japonicae Flos, Forsythiae Fructus, Verbenae Herba, and Carthami Flos have different types of active compounds that have therapeutic effects on COVID-19 (Huang et al., 2021; Niu et al., 2021).

### THE CLINICAL EFFICIENCY OF THREE CHINESE MEDICINES AND THREE CHINESE RECIPES

The COVID-19 pandemic is still ongoing and affects individuals in different ways. Therefore, disease progression has been classified into three stages according to signs, symptoms, and disease severity, e.g., stage I, stage II, and stage III. Stage I begins with upper respiratory tract symptoms such as dry cough, fever, tiredness, etc. COVID-19 stage II is also called the inflammation phase in which infected patients are diagnosed with pneumonia without hypoxia or with hypoxia. Normally, patients diagnosed with pneumonia with hypoxia need hospitalization and oxygen supplementation. Stage III, also known as the hyper-inflammation phase, in which an infected patient’s health...
suddenly worsens, typically develops acute respiratory distress syndrome (ARDS). Most of the COVID-19-related deaths occur in this phase. Keeping in view the importance of the COVID-19 infection developmental stages, the NHC has also issued recommendations for clinicians to use the three Chinese medicines and three Chinese recipes under specific signs and symptoms (Table 2). LHQW and JHQG have been recommended for use in patients with fatigue, fever, etc. XFBD and HSBD are recommended for treating moderate and severe cases, respectively. XBJ can be used only in critical cases, while QFPD is recommended for both non-critical and critical patients. Details of clinical applications of individual drugs are given below.

QFPD was used in 214 COVID-19 patients in four provinces and was found to have a therapeutic response rate of over 90% after comprehensive evaluation (Medicineo NAO ITC XXXo). Different direct or indirect evidence-based studies have endorsed QFPD for the treatment of COVID-19 (Cao et al., 2020; Liang et al., 2020; Zhang et al., 2020a). Additionally, QFPD is the only TCM drug recommended for the treatment of all stages of COVID-19 cases. Thousands of COVID-19 patients have been recovered with QFPD administration, and it also stops the progression of the mild disease to the critical stage (Zhao et al., 2020; Zhong et al., 2020). In a retrospective multicenter study, 782 patients with mild-to-moderate COVID-19 were allocated to take QFPD. Results showed that early QFPD administration is linked to quicker recovery, decreased hospital stay, and decreased virus shedding time. In addition, the mortality rate was 0.3%, which is much lower than the global average mortality, proving the effectiveness of QFPD in treating COVID-19 (Shi et al., 2020). Another study (Xin et al., 2020) found that combining QFPD with Western medicine can improve COVID-19 symptoms and lung inflammation (Xin et al., 2020). Furthermore, studies suggest that combining QFPD with alpha-interferon, oseltamivir, phosphate, chloroquine, arbidol, and ribavirin to treat COVID-19 can reduce hospitalization stays and improve clinical symptoms and lung CT (Hu et al., 2020; Yang et al., 2020). Zhang et al. (2021) found that QFPD administration can decrease the mortality ratio. It is important to note that QFPD administration did not raise the risk of organ injury. A study of 76 COVID-19 patients from Hebei province, China, has reported that QFPD can control clinical symptoms and improve blood parameters with few adverse reactions (Rahaman et al., 2019).

XBJ is a novel TCM injectable drug that has been extensively used for critical COVID-19 patients and has decreased inflammation storm and increased the blood oxygen level (Pan et al., 2020), which are two typical symptoms in critical COVID-19 cases (Huang et al., 2020b). XBJ was injected into 42 mild and severe COVID-19 cases for a week, and CT reports showed that 60% of the patient’s lung capacity had improved, the time of nucleic acid becoming negative was shorter, and thus the patient’s stay in the hospital had also been shortened. Moreover, the patient’s CBC reports showed that the patient’s white blood cell, neutrophil, platelet, and fibrinogen counts were increased. Meanwhile, the patient’s interleukin (IL)-6, IL-10, CRP, and d-dimer levels also decreased after treatment (Guo et al., 2020). Another study that compared the XBJ group (XBJ + routine medicine) with the control group (0.9% NaCl + routine medicine) showed that XBJ could cut down the rate of ARDS and artificial supplication. Moreover, it can also reduce septic shock and stop disease progression from severe to critical. The cardinal symptoms (fever, cough, fatigue, and shortness of breath) in the XBJ-treated group were shorter than those in the control group, and they remained in the ICU for a lesser time compared to the control. Furthermore, IL-6, IL-8, and tumor necrosis factor alpha (TNF-α) counts were significantly reduced, without any anaphylactic shock (Luo et al., 2021). Zhang et al. (2020b) reported that lung inflammation could be absorbed better by treating it with XBJ. It has been explained in an in vitro study that XBJ use keeps cells safe from virus-induced cell death. Furthermore, it also protects the normal size of cells and inhibits plaque count in XBJ-treated cells in a dose-dependent
TABLE 3 | Possible mechanism of action of the National Health Commission (NHC)-approved Chinese drugs against COVID-19.

| Drugs | Direct targets | Indirect targets | Pathways | References |
|-------|----------------|-----------------|----------|------------|
| QFPD  | ACE2, 3CLpro, and PLpro | AKT1, MAPK1, MAPK14, IL-6, and TNF | NF-κB, TNF, MAPK | Chen et al. (2020), Xu Tian-fu and Yang (2020), Ren et al. (2021) |
| HSBD  | ACE2, 3CLpro, and PLpro | IL-6, MAPK8, MAPK1, and IL-1β | TNF, PI3K-Akt, NOD-like receptor, MAPK, and HIF-1α | Lai et al. (2020), Tao et al. (2020), Ren et al. (2021) |
| LHQW  | ACE2, 3CLpro, and PLpro | IL-6, TNF, MAPK1, IL-1β, MAPK8, CCL2, CASP1,3, NLRP3, NFKB1, NF-ÎB, etc. | Toll-like receptor, NOD-like receptor, IL-17, TNF, and MAPK | Ren et al. (2021), Wang et al. (2021a) |
| JHQG  | ACE2, 3CLpro, and PLpro | IL-6, IL-1β, OXCL8, CCL2, IL-2, IL-4, ICAM1, IL-10, IFNG, IL-1A, etc. | PI3K-Akt, TNF, and Toll-like receptor | Qi and Wang (2016), Simayi MN et al. (2020), Ren et al. (2021) |
| XFBD  | ACE2 and 3CLpro | IL-6, MAPK3, MAPK1, MAPK14, MAPK8, IL-1β, CCL2, EGFR, PPARG, NOS2, TTR, AKT1, FYN, TP53, rep, etc. | Toll-like receptor, NF-κB, PI3K-Akt, and T-cell receptor | Dai et al. (2020), Ren et al. (2021), Tianyue and Lijing (2021), Xing et al. (2020), Zheng et al. (2020) |
| XBJ   | ACE2 and 3CLpro | AKT1, IL-6, TNF, TP53, CASP3, IL-10, MAPK8, MAPK1, L1B8, CCL2, IL-4, etc. | PI3K-Akt, TNF, MAPK, and IL-17 | | |

manner compared to the control (Ma et al., 2020). Another study that used XBJ on 31,913 patients reported that the probability of side effects was 0.3% (Ma et al., 2020).

Recently, LHQW was administered to 245 COVID-19 patients. The results showed that it could effectively improve clinical symptoms (fever, cough, and fatigue). Furthermore, it also stops the disease's progression (Zhuang et al., 2021). In addition, LHQW, compared with arbidol, can recover lung inflammation with no serious side effects (Yu et al., 2020). Compared with conventional therapy, LHQW treatment can improve fever more effectively (Lv et al., 2020; Yao et al., 2020; Zeng et al., 2020). One clinical retrospective analysis recruited 154 COVID-19 patients treated with LHQW and found that the probability of symptom remission was higher than the control group (Zeng et al., 2020). In another study, LHQW was administrated to 142 COVID-19 patients for 14 days, and it revealed that LHQW has a significantly increased recovery rate and lung CT (Hu et al., 2021). LHQW was used on 51 moderate COVID-19 patients plus conventional therapy, and results showed that it has a high rate of fever improvement and a low rate for the illness getting worse; furthermore, LHQW also improved the lung CT images (Cheng et al., 2020). Xiao et al. (2020) reported that COVID-19 patients treated with the combination of LHQW, Huoxiang Zhengqi, and Western medicine could recover clinical symptoms by improving the efficacy of anti-infective drugs and prognosis.

THE POSSIBLE MECHANISM OF ACTION OF THE THREE CHINESE MEDICINES AND THREE CHINESE RECIPES

SARS-CoV-2 enters into the host through virus spikes and human ACE2 (hACE2) interaction called receptor-binding domain (RBD), proteolytically activated by cell surface protease TMPRSS2, lysosomal proteases cathepsin, etc. (Zhou et al., 2020; Sun et al., 2021). Furthermore, this entry pattern contributes to the rapid spread and onset of severe symptoms and high fatality of infected patients. Therefore, ACE2 and TMPRSS2 are considered candidates for the development of antiviral agents. To date, multiple (both TCMs and Western) drugs have shown a direct or indirect antiviral effect on COVID-19, but most of the available anti-COVID-19 drugs', particularly TCMs, mechanism of action in vitro or in vivo is yet unclear. Multiple components of the three Chinese medicines and three Chinese recipes have downregulated the expression of ACE2 by regulating different transcription factors (Niu et al., 2020; Niu et al., 2021). Additionally, some reports have highlighted that different components of three Chinese medicines and three Chinese recipes have inhibited the replication of SARS-CoV-2 (Huang et al., 2021). Here, we summarize the three Chinese medicines and three Chinese recipes' predicted mechanisms of action individually (Table 3).

QFPD decoction in English means lung cleansing and detoxifying decoction (Cao et al., 2020). ACE, ACE2, AGTR1, FURIN, TNF, CASP3, CASP6, DPP4, CL1, and POLD1 have also been predicted as QFPD targets in treating COVID-19 (Yan et al., 2020). Another report, based on the molecular docking technique, mentioned that QFPD could directly act on the 3CLpro and block its multiplication and ACE2 to reduce virus entry into cells (Wu et al., 2020). It has been suggested that QFPD has the highest number of targets for binding with various transcriptional factors (Chen et al., 2020). A total of 217 QFPD composition-related targets and 200 COVID-19 related targets were predicted. Finally, 51 related targets, including FOS, IL-6, CCL2, and IL-1α, were declared key targets (Xu et al., 2020). It has been reported that QFPD significantly reduced the release of IL-6 from macrophages by activating both LPS and poly (I:C)/Pam3CSK4. Therefore, it exerts moderate anti-inflammatory effects through the Toll-like receptor pathways (Yang et al., 2020). It has been further reported that the Toll-like signaling pathway has a vital role in the mechanism of QFPD action against COVID-19 treatment. Different QFPD components may directly interact with the Toll-like receptor four and control the mitogen-activated protein kinase (MAPK) signaling pathway and nuclear factor kappa B (NF-κB) signaling pathway to inhibit the secretion of IL-1β, TNF-α, IL-8, etc. (Yang et al., 2020). In COVID-19 patients, the QFPDD treatment demonstrated induced immunity, anti-inflammation, and organ protection, elucidating the QFPDD...
formula’s application in the SARS-CoV-2 campaign. According to one study, 12 bioactive components in QFPDD identified 623 targets, 88 of which overlapped with genes affected by SARS-CoV-2 infection. These target sites involve biological processes such as hemostasis; cell growth; pattern recognition receptor signaling; IL signaling; and COVID-19-related nervous, circulatory, and digestive system injuries. A pathway analysis also revealed 55 critical targets for QFPDD, which regulated five functional modules, including induced immunity, anti-inflammation, and organ protection. Baiacal, hesperidin, hyperoside, and glycyrrhizic acid were linked to seven key targets: AKT1, HMOX1, IL-6, IL-10, PTGS-2, TNFa, and TP53. Molecular docking analysis revealed that key components in QFPDD might bind to six host proteins, which then interact with COVID-19 virus proteins, thereby supporting QFPDD’s anti-SARS-CoV-2 effect (Zhao et al., 2021b).

Wang et al. (2020) predicted that there are 99 active compounds in XFBD, among which 22 can bind to ACE2 and 3CLpro proteins with binding properties similar to ribavirin, lopinavir, and ritonavir. Finally, IL-6, MAPK3, MAPK1, MAPK14, MAPK8, IL-1β, CCL2, EGFR, PPARG, and NOS2 were declared key targets of XFBD for COVID-19 (Wang et al., 2020). TTR, AKT1, FYN, and TP53 have been proposed as the main targets for XFBD; additionally, TP53 has a strong relationship with COVID-19 (Wang et al., 2021b). A clinical retrospective analysis of 42 COVID-19 patients suggests that XFBD together with conventional medicine can effectively relieve clinical symptoms, including cough, fever, shortness of breath, fatigue, etc. (Xiong et al., 2020). Furthermore, they also found that XFBD treatment also significantly raised lymphocytes and white blood cell count and decreased C-reactive protein and erythrocyte sedimentation rate (Xiong et al., 2020). Another report found that XFBD treatment has recovered severe COVID-19 cases with 13 days of treatment (Zhou et al., 2021b).

HSBD can be linked with ACE2 and 3CLpro (Lai et al., 2020; Xie et al., 2020). MAPK3, MAPK8, TNF, IL-6, and TP53 were declared as the main targets of HSBD for the treatment of COVID-19 (Tao et al., 2020). Other research initially predicted 45 potential targets for HSBD. Finally, RELA, TNF, IL-6, IL-8, MAPK14, TP53, CCL2, MAPK3, MAPK1, IL-4, MAPK8, CASP8, and STAT1 were declared key targets of HSBD for the treatment of severe COVID-19 patients (Zhu et al., 2021). By comparing different studies, we found that IL-6, TNF, RELA, MAPK1, MAPK8, CCL2, IL1B, MAPK14, TP53, CCL2, IL-2, PTGS2, and IFNG were the key targets for HSBD treatment of COVID-19 (Lai et al., 2020; Liu et al., 2020; Tao et al., 2020; Xie et al., 2020; Niu et al., 2021; Zhu et al., 2021).

Shen et al. (2020) suggested that HSP90AA1, AKT1, RELA, ACE2, and 3CLpro were also the five key targets for JHQG for the treatment of COVID-19. Using the DrugBank database, Lin et al. (2020) predicted 263 QFPD targets, compared them with 346 COVID-19 possible targets, and found 49 identical targets. Among them, IL-6, IL-1β, CCL18, CCL2, IL-2, IL-4, ICAM1, IL-10, IFNG, and IL-1A are seen as important targets of JHQG for treating COVID-19 (Lin et al., 2020), and all of them are related to immune regulation (Chen et al., 2019). Peng et al. (2020) reported 720 potential targets for JHQG and predicted 253 disease targets by using the GeneCard and OMIM databases. Finally, they predicted 79 possible treatment targets; among them, 18 key targets were obtained, including MAPK1, MAPK3, TP53, JAK1, FOS, CASP3, IFNG, TNF, IL-1β, CCL18, NFKB1, IL-6, PIK3CA, MAPK8, RELA, CASP8, IL-2, and MAPK14 (Peng et al., 2020). The TCMSP and SwissTargetPrediction databases found 414 treatment targets for QHQG, while the GeneCards database suggested 346 disease targets. Finally, 47 targets were shortlisted, among which eight were the core targets (MAPK1, CASP3, TP53, ALB, TNF, IL-6, MAPK8, and MAPK14) of QHQG for COVID-19 treatment (Mao et al., 2020).

It has been predicted that three XBJ ingredients (quercetin, beta-sitosterol, and luteolin) can combine with ACE2 and 3CLpro to achieve an antiviral effect (Dai et al., 2020). Another study suggested that XBJ can attach to 3CLpro, ACE2, and S protein (Xing et al., 2020). Zhao et al. identified 44 active ingredients, after comparing the potential targets of XBJ with COVID-19 targets, and they suggested 44 treatment targets such as AKT1, TP53, TNF, JUN, EGFR, IL-1β, IL-10, and EGF. Among them, AKT1 was identified as the core target, while two more active ingredients, luteolin and quercetin in XBJ, have a broad-spectrum effect on COVID-19 (Tianyu and Liying, 2021). Another study predicted 52 potential targets of XBJ for treating COVID-19, including IL-6, TNF, TP53, CASP3, IL-10, MAPK8, MAPK1, IL1B, CCL2, IL-4, etc., and it is thought to be involved in immune responses (Dai et al., 2020). According to another report, there were 144 potential therapeutic targets of XBJ against COVID-19, of which GAPDH, TNF, CASP3, EGFR, MAPK1, PTGS2, STAT3, and MAPK8 had high degree values by PPI network analysis. Moreover, these targets involved multiple inflammations and immune-related issues (Zheng et al., 2020).

LHQW contains a total of 13 TCM compounds; therefore, it is hard to describe the composite mechanisms of each component of LHQW action against COVID-19. A total of 160 active components were found in LHQW, with 57 target proteins, such as IL-6, MAPK1, HSP90AA1, CCL2, CASP1, NLRP3, NFKB1, and TNF, linking 35 signaling pathways such as the Toll-like receptor signaling pathway and the NOD-like receptor signaling pathway (Yan and Zou, 2021). Another study reported a total of 224 chemical components were obtained in LHQW, for 246 targets, such as IL-6, TNF-α, CASP3, NF-j B, and signaling pathways, MAPK, IL-17, and TNF (Weipan Peng et al., 2020).

Two retrospective observational studies (Cheng et al., 2020b; Yao et al., 2020) found that combining LHQW with a conventional drug significantly accelerated the relief of fever, cough, and fatigue in COVID-19 patients. At the molecular level, LHQW inhibited SARS-CoV-2 replication and pathogenesis by reducing pro-inflammatory cytokine production (Runfeng et al., 2020). In clinical trials, LHQW administration is an effective treatment for COVID-19 patients. A combination of high-resolution mass spectrometry and an untargeted data mining approach analyzed LHQW components in treated COVID-19 patient plasma and urine. This combination identified 132 bioactive components in LHQW that humans absorbed via the gastrointestinal tract. The pharmacological characteristics of eight components identified in LHQW with a
potential affinity for ACE2 receptors were further evaluated using data from comprehensive ACE2 screening using chromatography. The results show that forsythoside-A, forsythoside-I, rhein, neochlorogenic acid, and other components have a strong inhibitory effect on ACE2. This study investigated the molecular therapeutic mechanisms of LHQW treatment, demonstrating the utility of the COVID-19 patient exposure-based approach in identifying bioactive components in TCMs (Chen et al., 2021).

CONCLUSION AND FUTURE RECOMMENDATIONS

The three Chinese medicines and three Chinese recipes are effective in the treatment and prevention of COVID-19 infections. In China, the three Chinese medicines and three Chinese recipes were used to treat COVID-19 infections, significantly alleviating disease symptoms, delaying mild disease progression to a severe stage, improving cure rates, and decreasing mortality rates. The three Chinese medicines and three Chinese recipes have been demonstrated to be highly effective against COVID-19, but there is a lack of evidence. Available literature analysis, in silico, and other types of studies suggest that the three Chinese medicines and three Chinese recipes may have antiviral, immune regulation, organ protection, and anti-inflammation actions via multi-component-based drugs that act on multiple targets in the host by employing multiple pathways for COVID-19 treatments. However, most of the available data related to the potential mechanism of the three Chinese medicines and three Chinese recipes is based on virtual simulation, which is acquired via molecular docking and network pharmacology analysis, where different researchers employed different components, targets, and pathways to predict the possible mechanism of action (Table 3). These predictions have not yet been proven. Therefore, there is a need for high-quality in vitro and in vivo clinical studies by employing new strategies and technologies, such as genomics, metabolomics, and proteomics, to verify the predicted mechanisms of these drug’s effects on COVID-19.

There has been a continuous debate for many decades among the world scientific community about the quality standards, pharmacodynamics, effective material basis, unclear toxicity, and efficacy of TCM. The ongoing COVID-19 pandemic and TCM therapeutic effects have once more become the bone of contention. Therefore, China’s national and provincial governments should initiate different projects to explore active components of TCMs, their mechanisms of action, quality control standards, TCM efficacy evaluations, and clinical studies with the help of modern industrial technologies.

AUTHOR CONTRIBUTIONS

All authors contributed to the concept of this study; ZB, designed the study; K-YX, TS, ZZ, J-YW, and ZB wrote the manuscript; all authors reviewed and approved it for publication.

FUNDING

The work was supported by the key research and development program (20203AC100006) and a grant from the Chinese Academy of Traditional Chinese Medicine of China (ZZ13-035-04).

REFERENCES

Ang, L., Lee, H. W., Choi, J. Y., Zhang, J., and Soo Lee, M. (2020). Herbal Medicine and Pattern Identification for Treating COVID-19: a Rapid Review of Guidelines. Integr. Med. Res. 9 (2), 100407. doi:10.1016/j.imr.2020.100407

Bl, Z. (2020). Xuanfei Baidu Granules Is a Product of “Chinese Medicine + Technology.”

Cao, P., Wu, S., Wu, T., Deng, Y., Zhang, Q., Wang, K., et al. (2020). The Important Role of Polysaccharides from a Traditional Chinese Medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 Pandemic. Carbohydr. Polym. 240, 116346. doi:10.1016/j.carbpol.2020.116346

Cavalieri, S., and Rotoli, M. (1997). Huangdi Neijing: a Classic Book of Traditional Chinese Medicine. Recenti Prog. Med. 88 (11), 541–546.

Chen, F. P., Chen, F. J., Jong, M. S., Tsai, H. L., Wang, J. R., and Hwang, S. J. (2009). Modern Use of Chinese Herbal Formulas from Shang-Han Lun. Chin. Med. J. (Engl) 122 (16), 1889–1894.

Chen, H., Wang, F., Zhang, P., Zhang, Y., Chen, Y., Fan, X., et al. (2019). Management of Cytokine Release Syndrome Related to CAR-T Cell Therapy. Front. Med. 13 (5), 610–617. doi:10.1007/s11684-019-0714-8

Chen, J., Wang, Y. K., Gao, Y., Hu, L. S., Yang, J. W., Wang, J. B., et al. (2020). Protection against COVID-19 Injury by Qingfei Paodu Decoction via Anti-viral, Anti-inflammatory Activity and Metabolic Programming. Biomed. Pharmacother. 129, 110281. doi:10.1016/j.biopha.2020.110281

Chen, X., Wu, Y., Chen, C., Gu, Y., Zhu, C., Wang, S., et al. (2021). Identifying Potential Anti-COVID-19 Pharmacological Components of Traditional Chinese Medicine Lianhuaqingwen Capsule Based on Human Exposure and
Dai, Y. J., Jiang, L., Gao, J. R., and Guo, M. F. (2020). Study on COVID-19 Mechanism of Xuebijing Injection by Network Pharmacology and Molecular Technology. Chin. J. Hosp. Pharm. 21, 2233–2237. doi:10.3866/mzph.2020.521.2020.015
Ding, Y., and Giannoumis, G. A. (2017). Information and Communications Technology and Social Media Accessibility in China. Chin. Soc. Media, 130–143. doi:10.4324/9781315160214-13
Ding, Y., Zeng, L., Li, R., Chen, Q., Zhou, B., Chen, Q., et al. (2017). The Chinese Prescription Lianhuangweng Capsule Exerts Anti-inflammatory Activity through the Inhibition of Viral Propagation and Impacts Immune Function. BMC Complement. Altern. Med. 17 (1), 130. doi:10.1186/s12996-017-1585-7
Duan, C., Xia, W. G., Zheng, C. J., Sun, G. B., Li, Z. L., Li, Q. L., et al. (2020). Clinical Observation on Jinhua Qinggan Granule Combined with Conventional Western Medicine Therapy in Treating Mild Cases of Coronavirus Disease 2019. Chin. Med. J. 17, 1473–1477.
Fehr, A. R., and Perlman, S. (2015). Coronaviruses: an Overview of Their Functional Properties of SARS-CoV-2 Spike Protein: Potential Antivirus Drug Development for COVID-19. Acta Pharmacol. Sin. 41 (1). doi:10.1042/BSR20202583
Feng, L., Xue, W., Cao, W. Y., Wu, Z. G., Chao, Y. C., and Liang, C. (2021). Network Pharmacology for the Identification of Phytochemicals in Traditional Chinese Medicine for COVID-19 that May Regulate ACE2 and IL-6. Biosci. Rep. 41 (1). doi:10.1042/BSR2020583
Huang, K., Zhang, P., Zhang, Z., Youn, J. Y., Wang, C., Zhang, H., et al. (2021). Progress Has Been Made in Screening Effective TCM Prescriptions. Medicine NCTD (XXXa). Hua-shi-Bai-du Granule: Ancient and Innovative Crystallization of Traditional Chinese Medicine Wisdom. Medicine NCTD (XXBb). People’s Daily Reported that Qingfei Tieduo Decoction: Anti-epidemic, TCM Added New Strength. Medicine NCTD (XXXc). Progress Has Been Made in Screening Effective TCM Prescriptions. Medicine NCTD (XXXd). These Traditional Chinese Medicine Prescriptions Are Effective in Treating COVID-19, and “Three TCM Patented and Three TCM Prescriptions” Write the TCM Anticancer Plan. Medicine NCTD (XXXe). Zhan Boli Xuanfei Baidu Granule Is the Product of Chinese Medicine + Science and Technology.
Hu, K., Guan, W. B., Li, Y. B., Zhang, W., Li, Z., Wang, B., et al. (2021). Efficacy and Safety of Lianhuangweng Capsules, a Repurposed Chinese Herb, in Patients with Coronavirus Disease 2019: A Multicenter, Prospective, Randomized Controlled Trial. Phytomedicine 85, 135242. doi:10.1016/j.phymed.2020.135242
Hu, W. H., Wu, F., Cao, W. Y., Wu, Z. G., Chao, Y. C., and Liang, C. (2021). Network Pharmacology of Jinhua Qinggan Granules in the Treatment of Coronavirus Disease 2019. J. Tradit. Chin. Med. Mater. 11, 2843–2849.
for COVID-19 Based on "The Diagnosis and Treatment Program for Coronavirus Disease-2019" from Chinese Authority. *Am. J. Chin. Med.* 48 (5), 1035–1049. doi:10.1142/S0192415X20500500
Zhao, Z., Li, Y., Zhou, L., Zhou, X., Xie, B., Zhang, W., et al. (2021). Prevention and Treatment of COVID-19 Using Traditional Chinese Medicine: A Review. *Phytomedicine* 85, 153308. doi:10.1016/j.phymed.2020.153308
Zheng, W. J., Yan, Q., Ni, Y. S., Zhan, S. F., Yang, L. L., Zhuang, H. F., et al. (2020). Examining the Effector Mechanisms of Xuebijing Injection on COVID-19 Based on Network Pharmacology. *BioData Min* 13, 17. doi:10.1186/s13040-020-00227-6
Zhong, L. D., Lam, W. C., Yang, W., Chan, K. W., Sze, S. C. W., Miao, J., et al. (2020). Potential Targets for Treatment of Coronavirus Disease 2019 (COVID-19): A Review of Qing-Fei-Pai-Du-Tang and its Major Herbs. *Am. J. Chin. Med.* 48 (5), 1051–1071. doi:10.1142/S0192415X20500512
Zhong, Y., Zhou, J., Liang, N., Liu, B., Lu, R., He, Y., et al. (2016). Effect of Maxing Shigan Tang on H1N1 Influenza A Virus-Associated Acute Lung Injury in Mice. *Intervirology* 59 (5-6), 267–274. doi:10.1159/000458726
Zhou, L. W. X., Liu, X. K., Fei, X., Liu, L., et al. (2021). Case Report of Severe COVID-19 Patients Treated with Xuanfeibaidu Prescription. *Tianjin J. Traditional Chin. Med.* 5, 556–559.
Zhou, L., Xu, Z., Castiglione, G. M., Soberman, U. S., Eberhart, C. G., and Duh, E. J. (2020). ACE2 and TMPRSS2 Are Expressed on the Human Ocular Surface, Suggesting Susceptibility to SARS-CoV-2 Infection. *Ocul. Surf.* 18 (4), 537–544. doi:10.1016/j.jtos.2020.06.007
Zhou, P., Li, Z., Xie, L., An, D., Fan, Y., Wang, X., et al. (2021). Research Progress and Challenges to Coronavirus Vaccine Development. *J. Med. Virol.* 93 (2), 741–754. doi:10.1002/jmv.26517
Zhu, Y. W., Yan, X. F., Ye, T. J., Hu, J., Wang, X. L., Qiu, F. J., et al. (2021). Analyzing the Potential Therapeutic Mechanism of Huashi Baidu Decoction on Severe COVID-19 through Integrating Network Pharmacological Methods. *J. Tradit Complement. Med.* 11 (2), 180–187. doi:10.1016/j.jtcme.2021.01.004
Zhuang, W., Fan, Z., Chu, Y., Wang, H., Yang, Y., Wu, L., et al. (2020). Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China. *Front. Pharmacol.* 11, 1066. doi:10.3389/fphar.2020.01066
Zuo, L., Sun, Z., Wang, Z., Ding, D., Xu, T., Liu, L., et al. (2019). Tissue Distribution Profiles of Multiple Major Bioactive Components in Rats after Intravenous Administration of Xuebijing Injection by UHPLC-Q-Orbitrap HRMS. *Biomed. Chromatogr.* 33 (2), e4400. doi:10.1002/bmc.4400
Zuo, L., Zhong, Q., Wang, Z., Sun, Z., Zhou, L., Li, Z., et al. (2017). Simultaneous Determination and Pharmacokinetic Study of Twelve Bioactive Compounds in Rat Plasma after Intravenous Administration of Xuebijing Injection by UHPLC-Q-Orbitrap HRMS. *J. Pharm. Biomed. Anal.* 146, 347–353. doi:10.1016/j.jpba.2017.09.010

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xia, Zhao, Shah, Wang and Baloch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.